OneCyte, a leader in high-throughput single-cell analysis, and Kemp Proteins, a pioneer in protein engineering, have announced a strategic partnership to deliver faster, more efficient cell line development for biopharmaceutical companies worldwide. 

The collaboration merges OneCyte’s proprietary single-cell platform—which enables high-throughput, high-sensitivity clone selection—with Kemp Proteins’ advanced molecular engineering, including its machine learning–driven PROTiQ platform.  

Together, the companies aim to accelerate development timelines, boost yields, and enable expression of complex biologics, including non-monoclonal antibody formats and emerging therapeutic modalities. 

Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules—challenges that can delay clinical progress.  

The OneCyte-Kemp partnership tackles these issues head-on by integrating predictive in silico design with rapid experimental validation. Kemp’s PROTiQ platform evaluates amino acid sequences to flag developability risks, identify sequence liabilities, and provide structural insights. Optimized candidates are then matched with OneCyte’s high-performance platform to rapidly select elite, high-producing clones. 

The partnership also offers access to a royalty-free CHO-K1 GS knockout cell line and transposase-based expression system, giving biopharma companies flexible development options without restrictive licensing. Unlike traditional workflows, this integrated approach adapts to new therapeutic modalities, delivering speed and performance without compromise. 

"We are thrilled to be working with Kemp to provide industry-leading cell line development services to the biopharma industry," said Konstantinos Tsioris, Co-founder and President of OneCyte.  

"By combining our single-cell technology with Kemp's deep expertise in protein expression, we are confident that we can address the hardest challenges associated with new modalities, delivering faster timelines and industry-leading titers." 

"As Kemp has been at the forefront of protein expression for many years, this partnership positions us to extend and strengthen that leadership," said Michael Keefe, CEO of Kemp Proteins. "OneCyte's class-leading single-cell technology, stacked on top of our molecular design and expression capabilities, will provide a powerful and differentiated solution for our global biopharma customers."